share_log

Soligenix Enters Into Exclusive Option Agreement With Silk Road Therapeutics For Rights To Topical Pentoxifylline Designed To Treat Behçet's Disease

Soligenix Enters Into Exclusive Option Agreement With Silk Road Therapeutics For Rights To Topical Pentoxifylline Designed To Treat Behçet's Disease

Soligenix 与 Silk Road Therapeutics 签订独家期权协议,以获得旨在治疗白塞氏病的局部用己酮可可碱的权利
Benzinga ·  2023/05/01 07:37

Soligenix Enters into Exclusive Option Agreement With Silk Road Therapeutics For Rights To Topical Pentoxifylline Designed To Treat Behçet's Disease

Soligenix 与 Silk Road Therapeutics 签订独家期权协议,以获得旨在治疗 Beh√βset 病的局部用己酮可可碱的权利

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发